151.22 USD
↘ 0.47 (0.31%)AT CLOSE (11:59 AM EDT)
Palvella Therapeutics, Inc. Common Stock
PVLANASDAQ • USD
151.37
↗ 0.15 (0.10%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
151.37
↗ 0.15 (0.10%)
Market: CLOSED
PVLA is currently priced at $151.49. The stock presents a mixed profile: our models indicate a Buy for technical indicators, while underlying fundamentals flash a Sell. This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On the valuation front, PVLA trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Sep 15, 2026.
Open?$152.72
High?$155.63
Low?$148.15
Prev. Close?$151.69
Volume?215.6K
Avg. Volume?187.3K
VWAP?$149.95
Rel. Volume?1.15x
Bid / Ask
Bid?$124.70 × 100
Ask?$178.51 × 100
Spread?$53.81
Midpoint?$151.61
Valuation & Ratios
Market Cap?2.2B
Shares Out?14.4M
Float?11.9M
Float %?82.8%
P/E Ratio?N/A
P/B Ratio?10.08
EPS?-$4.28
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
Employees
29
Market Cap
2.2B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2024-12-16
Address
353 W. LANCASTER AVENUE
WAYNE, PA 19087
Phone: (484) 253-1461
WAYNE, PA 19087
Phone: (484) 253-1461
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?23
Short Sent.?34
Piotroski F-Score?0/9Weak
Altman Z-Score?35.22Safe
Confidence?45%Low
Short InterestVery High
Short % of Float?19.31%High
Short Interest?2.3M
Days to Cover?11.1
Free Float11.9M
Avg Daily Volume205.6K
Settlement Date2026-08-31
Financial Health
Current Ratio?21.18Strong
Quick Ratio?21.18Strong
Cash Ratio?15.72Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?10.08HIGH▾
Peers100
S&P19
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-34.6CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-28.4%WEAK▾
S&P6
ROA?-24.3%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-36513000
Enterprise Value?$2.0B
Fundamentals ratios updated end of day